|
Abstract Background 2005 issued by the International Diabetes Federation (International Diabetes Federation IDF) the MS global consensus defined abdominal obesity as a prerequisite for the diagnosis of metabolic syndrome (Metabolic syndrome, MS), the importance of abdominal obesity in metabolic disorders importance. Abdominal obesity is an independent risk factor for coronary heart disease, type 2 diabetes, cerebrovascular disease, hyperlipidemia. Because different parts of the fat have different metabolic and endocrine, abdominal obesity may be due to the accumulation of intra-abdominal fat secretion of the quality and quantity of the other relevant factors change, triggered by the MS. Adiponectin (adiponectin, ADPN), resistin (resistin, RETN) and adipocyte fatty acid binding protein (adipocyte fatty acid-binding protein, A-FABP) is a recently discovered adipokines secreted by fat cells, is thought to be Contact obesity, insulin resistance (Insulin Resistance, IR), MS with atherosclerosis important molecular basis. Research purposes of this study by measuring serum and adipose tissue of the abdominal obesity and MS patients ADPN, RETN, A-FABP level, aims to explore the abdominal obesity and the MS patients ADPN, RETN, A-FABP and waist circumference (Waist Circumference, WC ), BMI (body mass index, BMI), fasting glucose (fasting plasma glucose, FPG) and lipids and its clinical significance,-depth study ADPN, RETN, the physiological role of A-FABP mechanism, to further clarify obesity, the pathogenesis of MS, the theoretical basis for the prevention and treatment of obesity and MS. Methods 10 patients with abdominal obesity, according to the IDF diagnostic criteria 12 MS patients for the study. The object of the study of history taking, physical examination and blood samples and subcutaneous and omental adipose tissue specimens. Fasting serum ADPN, RETN and A-FABP levels measured by ELISA; the fat tissue ADPN, RETN and A-FABP mRNA expression was determined by RT-PCR method; simultaneous determination of the level of blood sugar, blood lipids and other related indicators. Results of the MS group, abdominal obesity group compared with the control group of subjects BMI, WC, WHR statistical difference (P lt; 0.01); systolic blood pressure (systolic blood pressure, SBP), diastolic blood pressure (diastolic blood pressure, DBP) and mean arterial blood pressure (mean arterial Blood Pressure ABPM) no significant difference among the three groups; triglycerides (triglycerides, TG) in the control group, abdominal obesity group, the MS group gradually increased (P lt; 0.01) abdominal obesity and MS patients with total cholesterol (total cholesterol, TC) than the control group increased high-density lipoprotein cholesterol (high density lipoprotein-cholesterol, HDL-C) is only reduced in the MS group (P lt; 0.05); FPG only increased in the MS group (P lt; 0.01). 2, serum ADPN in the MS group, abdominal obesity group than the control group reduced (P lt; 0.05), the MS group compared with abdominal obesity group had no significant difference; the serum retn, A-FABP increase in the MS group (P lt ; 0.05), and the MS group than the increase in abdominal obesity group (P lt; 0.05): Serum A-FABP in the MS group than the control group and central obesity were higher (P lt; 0.05) 3, omentum and subcutaneous fat tissue ADPN, RETN, A-FABP mRNA expression differences (P lt; 0.05) 4, abdominal obesity group, adiponectin mRNA expression in omental adipose tissues in the MS group were lower than the control group, the differences were statistically significant (P lt; 0.05); subcutaneous fat adiponectin mRNA expression level no significant difference. 5, abdominal obesity group, the MS group omental adipose tissue resistin mRNA relative expression levels were higher, the differences were statistically significant (P lt; 0.05); MS subcutaneous fat resistin mRNA expression levels The control group increased (P lt; 0.05). 6 the MS group omentum and subcutaneous adipose tissue adipocyte fatty acid binding protein mRNA relative expression levels than the control group, abdominal obesity group were significantly increased (P lt; 0.05). 7, omentum fat ADPN, RETN, A-FABP mRNA associated with BMI, WC, WHR (P lt; 0.05) The fat tissue ADPN, RETN, A-FABP mRNA expression (P lt; 0.05) Conclusion 1, subcutaneous and omental adipose tissue adiponectin, resistin, and adipocyte fatty acid binding protein expression differences, omental adipose tissue adiponectin expression was decreased, and the resistance to hormone and adipocyte fatty acid binding protein expression enhanced. 2, adiponectin, resistin and adipocyte fatty acid binding protein closely related to abdominal obesity, abdominal obesity in patients with decreased expression of adiponectin, resistin, and adipocyte fatty acid binding protein enhancement. 3, adiponectin, resistin, and adipocyte fatty acid binding protein in the presence of interrelated, decreased expression of adiponectin may be accompanied by enhanced expression of resistance to hormone and adipocyte fatty acid binding protein.
|